Ocular hemodynamic effects of nitrovasodilators in healthy subjects

Clin Pharmacol Ther. 2010 Jan;87(1):87-92. doi: 10.1038/clpt.2009.186. Epub 2009 Nov 4.

Abstract

Nitric oxide (NO) plays a key role in the regulation of ocular blood flow and may be an interesting therapeutic target in ocular ischemic disease. In the present study, we hypothesized that NO-releasing drugs may increase blood flow to the head of the optic nerve and also in the choroid. The study employed a randomized, placebo-controlled, double blind, four-way crossover design. On separate study days, 12 healthy subjects received infusions of nitroglycerin, isosorbide dinitrate, sodium nitroprusside, or placebo. All three study drugs reduced the mean arterial pressure (MAP) and ocular perfusion pressure (OPP) (P < 0.001). None of the administered drugs increased the ocular hemodynamic variables. By contrast, vascular resistance decreased dose dependently during administration of the study drugs (P < 0.001). These results indicate that systemic administration of NO-donor drugs is associated with a decrease in vascular resistance in the ocular vasculature. However, because these drugs also reduce blood pressure, they do not improve perfusion to the posterior eye pole.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cross-Over Studies
  • Double-Blind Method
  • Follow-Up Studies
  • Hemodynamics / drug effects*
  • Hemodynamics / physiology
  • Humans
  • Intraocular Pressure / drug effects
  • Intraocular Pressure / physiology
  • Male
  • Nitric Oxide Donors / pharmacology*
  • Optic Nerve / blood supply*
  • Optic Nerve / drug effects*
  • Optic Nerve / physiology
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology
  • Vasodilator Agents / pharmacology*
  • Young Adult

Substances

  • Nitric Oxide Donors
  • Vasodilator Agents